Dr Amy Chadwick (formerly Mercer) gained her first degree at The University of Liverpool, where she graduated with an MChem in Chemistry with Pharmacology (2002). She continued her studies at the interface of chemistry with pharmacology by completing a PhD under the supervision of Prof Paul O’Neill and Prof Kevin Park at the University of Liverpool which was focused upon elucidating the chemical and molecular mechanisms of cell death induced by the Artemisnin antimalarials (2006). Following this Amy completed a postdoctoral position in the Department of Pharmacology at the University of Liverpool with Kevin Park, funded by Pfizer Pharmaceuticals, in which she developed her knowledge of drug-induced liver injury. She then took up a position to use her skills and knowledge of cellular health and fundamental mechanisms of cell death as a Senior Postdoctoral Fellow at the newly established MRC Centre for Drug Safety Science where Amy began to develop her interest in drug-induced mitochondrial toxicity (2013). Following a period as a Tenure Track Fellow Dr Chadwick became a lecturer (2016) in the Department of Clinical & Molecular Pharmacology where she heads the Bioenergetics group, which has particular interest in the role of mitochondrial toxicity in drug-induced liver injury and the factors underlying the inter-individual response to drug-induced mitochondrial toxicity.
Prizes or Honours
- Early Career Investigator Prize (The British Toxicology Society, 2017)
- Poster Prize (Gordon Conference, 2011)
- IVTS Poster Prize (In Vitro Toxicology Society, 2010)